CT-388 is the only dual GLP-1R/GIPR agonist in development with near-perfect balanced potency at both receptors
4,21 There is also evidence to suggest GLP-1RAs can reduce motility in the small intestine
Fortunately, there are plenty of over-the-counter products that can help with GLP-1 constipation
For many people using drugs like semaglutide, tirzepatide, or retatrutide, this is an exciting (and increasingly realistic) possibility
GI adaptation: Lower doses allow the digestive system to adjust, reducing nausea and vomiting Triple receptor activation: Retatrutide's unique GLP-1/GIP/glucagon mechanism requires gradual introduction Safety monitoring: Assess individual response before increasing to therapeutic doses Injection site tolerance: Verify no local reactions before committing to higher doses What to Expect in the First Week During the initial retatrutide dose, you may experience: Mild appetite reduction (typically noticeable by days 2-3) Possible nausea, especially with large or fatty meals Minor injection site reaction (redness, mild swelling) Increased satiety after smaller portions Important: Don't be discouraged if you don't see significant weight loss at 2mg
Youll leave with a practical checklist you can take to your clinician, plus a clear understanding of how to protect muscle, heart, and brain while losing fat
